KUALA LUMPUR, Nov 15 — Pharmaniaga Bhd has managed to penetrate the international vaccine market with the first shipment of Sinovac “fill and finish” COVID-19 vaccine to Myanmar.
Pharmaniaga said the vaccine was prepared in the high technology facility of its wholly-owned subsidiary Pharmaniaga LifeScience Sdn Bhd that has been recognised by the European Union (EU).
“In Myanmar, the COVID-19 Sinovac vaccine will be distributed by Hemas Mandalar Pharmaceuticals Ltd, a pharmaceutical company in Myanmar which ordered 200,000 doses of the Sinovac fill and finish vaccine from Pharmaniaga.
“Recently, both companies had signed a memorandum of collaboration (MOC) for Pharmaniaga to supply the Sinovac vaccine to two private hospitals owned by Hemas Mandalar in Yangon. The delivery was done after getting the approval of the Myanmar Food and Drugs Authority,” the company said in a statement.
Pharmaniaga group managing director Datuk Zulkarnain Md Eusope said the cooperation with Hemas Mandalar will help expedite the private vaccination programme in Myanmar.
“The first fill and finish Sinovac shipment to Hemas Mandalar is a big success for Pharmaniaga. The 200,000 doses will be delivered in stages from Nov 13.
“Hopefully this cooperation with a major pharmaceutical company in Myanmar will open the door to more opportunities for us there,” he said.
